ReviewFrontiers in cardiovascular medicine2026
Cardiovascular complications in chronic active Epstein-Barr virus infection: a narrative review.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular involvement in chronic active Epstein-Barr virus (CAEBV) infection represents an uncommon yet severe spectrum of complications, including coronary artery lesions, arrhythmias, and pulmonary arterial hypertension. Reliable large-scale data for the management of CAEBV-associated cardiovascular damage are currently lacking. In this literature review, we aimed to summarize the clinical characteristics, pathological features, diagnostic approaches, and treatment strategies for CAEBV-related cardiac damage. This summary may enhance the awareness of CAEBV-associated cardiovascular complications and provide valuable insights for their clinical management. In this narrative review, we aimed to summarize the clinical characteristics, pathological features, diagnostic approaches, and treatment strategies for CAEBV-related cardiac damage. Methods: PubMed, Embase, Web of Science, CNKI, CQVIP, and Wanfang Data databases were searched as part of this narrative review to collect data on CAEBV infection with cardiovascular involvement and to summarize its characteristics, pathological features, diagnostic approaches, and treatment strategies. Results: We identified 32 articles reporting CAEBV-associated cardiovascular complications involving 57 patients with a median age of 11 years (range: 1-69 years). Among these patients, 19 (33.3%) were adults and 38 (66.7%) were children; 24 (42.1%) were male and 33 (57.9%) were female. Coronary artery lesions, electrocardiographic abnormalities, valvular regurgitation, and pericardial lesions were more frequent in children, whereas heart failure and pulmonary arterial hypertension were more prevalent in adults. Conclusions: Cardiovascular involvement in CAEBV infection is rare and presents substantial diagnostic and therapeutic challenges. The systematic evaluation of cardiovascular involvement is crucial for timely intervention and long-term surveillance. The poor prognosis of CAEBV-associated cardiovascular complications underscores the urgent need for further research to elucidate its pathogenic mechanisms and optimize therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.